Vivesto AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixi… Read more
Vivesto AB (VIVE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.021x
Based on the latest financial reports, Vivesto AB (VIVE) has a cash flow conversion efficiency ratio of -0.021x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.79 Million) by net assets (Skr133.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vivesto AB - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Vivesto AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Vivesto AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vivesto AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MOTHER
BK:MOTHER
|
N/A |
|
Export Inv
TA:EXPO
|
0.117x |
|
Paos Holdings Bhd
KLSE:5022
|
-0.042x |
|
THS Maple Holdings Ltd.
V:YAY
|
N/A |
|
Reliv International Inc
PINK:RELV
|
-0.027x |
|
Affimed NV
NASDAQ:AFMD
|
-0.648x |
|
Asiaplast Industries Tbk
JK:APLI
|
-0.037x |
|
Brite Tech Bhd
KLSE:0011
|
0.060x |
Annual Cash Flow Conversion Efficiency for Vivesto AB (2004–2024)
The table below shows the annual cash flow conversion efficiency of Vivesto AB from 2004 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr158.33 Million | Skr-47.25 Million | -0.298x | +14.14% |
| 2023-12-31 | Skr197.80 Million | Skr-68.74 Million | -0.348x | -40.46% |
| 2022-12-31 | Skr325.42 Million | Skr-80.52 Million | -0.247x | +6.56% |
| 2021-12-31 | Skr549.71 Million | Skr-145.56 Million | -0.265x | +11.23% |
| 2020-12-31 | Skr686.74 Million | Skr-204.86 Million | -0.298x | -3460.04% |
| 2019-12-31 | Skr819.39 Million | Skr-6.87 Million | -0.008x | +97.01% |
| 2018-12-31 | Skr424.05 Million | Skr-118.84 Million | -0.280x | +21.79% |
| 2017-12-31 | Skr345.04 Million | Skr-123.63 Million | -0.358x | +19.08% |
| 2016-12-31 | Skr300.37 Million | Skr-133.01 Million | -0.443x | -12.69% |
| 2015-12-31 | Skr326.05 Million | Skr-128.13 Million | -0.393x | -37.13% |
| 2014-12-31 | Skr375.71 Million | Skr-107.67 Million | -0.287x | +7.04% |
| 2013-12-31 | Skr281.91 Million | Skr-86.90 Million | -0.308x | -41.47% |
| 2012-12-31 | Skr319.15 Million | Skr-69.54 Million | -0.218x | -13.63% |
| 2011-12-31 | Skr273.47 Million | Skr-52.44 Million | -0.192x | +2.07% |
| 2010-12-31 | Skr294.17 Million | Skr-57.60 Million | -0.196x | -147.13% |
| 2009-12-31 | Skr141.80 Million | Skr-11.23 Million | -0.079x | -133.97% |
| 2008-12-31 | Skr61.21 Million | Skr14.28 Million | 0.233x | +167864.83% |
| 2007-12-31 | Skr64.81 Million | Skr9.00K | 0.000x | +100.07% |
| 2006-12-31 | Skr110.30 Million | Skr-22.73 Million | -0.206x | -7.71% |
| 2005-12-31 | Skr58.90 Million | Skr-11.27 Million | -0.191x | -192.02% |
| 2004-12-31 | Skr31.40 Million | Skr6.53 Million | 0.208x | -- |